地佐辛联合舒芬太尼治疗癌痛的临床效果

目的 探讨地佐辛联合舒芬太尼治疗癌痛的临床效果.方法 将80例癌痛患者随机分为3组,Ⅰ组采用0.3 mg/kg地佐辛治疗,Ⅱ组采用2.0μg/kg舒芬太尼治疗,Ⅲ组采用0.3 mg/kg地佐辛+2.0μg/kg舒芬太尼联合治疗.记录所有患者药物治疗前后生命体征的变化,用药后2、4、12、24、48 h的VAS镇痛评分和Ramsay镇静评分,以及用药后不良反应的发生情况.结果 3组患者用药前后生命体征均无明显变化(P>0.05),3组患者的VAS镇痛评分与治疗前比较明显下降(P<0.05),Ⅲ组各时段VAS镇痛评分均明显低于其他2组(P<0.05),且镇静评分及不良反应与其他两组比较无明显差异(P>0.05).结论 地佐辛联合舒芬太尼对癌痛的治疗效果好,且未增加不良反应,可以安全用于晚期癌症患者.

Clinical Efficacy of Dezocine Combined with Sufentanil on Cancer Pain

Objective To study the clinical efficacy of dezocine combined with sufentanil on cancer pain .Methods 80 cancer patients were randomly divided into 3 groups,groupⅠreceived 0.3 mg/kg dezocine treatment ,groupⅡreceived 2.0μg/kg sufentanil treatment ,groupⅢreceived 0.3 mg/kg +2.0μg/kg sufentanil combined with dezocine treatment .Changes of vital signs before and after drug treatment were recorded ,VAS pain score and Ramsay sedation scores of patients 2,4,12,24,48 h after medication,and adverse reactions were recorded .Results There showed no significant difference in vital signs before and after treatment of the 3 groups(P>0.05),VAS pain score of the 3 groups decreased significantly after treatment (P<0.05),VAS score in each period of group Ⅲwere significantly lower than those of the other 2 groups(P<0.05),and sedation score and ad-verse reactions compared with the other 2 groups had no significant difference (P>0.05).Conclusion Dezocine combined with sufentanil for cancer pain is effective without increase of adverse reactions ,and it can be safely used in patients with advanced cancer.